Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 50, 2013, Pages 20212-20217

  Feig, Christine ^a   Jones, James O ^a   Kraman, Matthew ^a   Wells, Richard J B ^a   Deonarine, Andrew ^b   Chan, Derek S ^a   Connell, Claire M ^a   Roberts, Edward W ^a,e   Zhao, Qi ^c   Caballero, Otavia L ^c   Teichmann, Sarah A ^d   Janowitz, Tobias ^a   Jodrell, Duncan I ^a   Tuveson, David A ^a,f   Fearon, Douglas T ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

KPC mouse; T cell exclusion; Tumor immunogenicity; Tumor stroma

Indexed keywords

ALPHA PROGRAMMED CELL DEATH 1 LIGAND 1 MONOCLONAL ANTIBODY; ANTI CYTOTOXIC T LYMPHOCYTE ASSOCIATED PROTEIN 4 MONOCLONAL ANTIBODY; ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CXCR4; FIBROBLAST ACTIVATION PROTEIN; GAMMA INTERFERON; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLERIXAFOR; PROTEIN; PROTEIN P53; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; HETEROZYGOSITY LOSS; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LEWIS CARCINOMA; METASTASIS; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR CELL LINE; TUMOR ESCAPE; TUMOR GROWTH; TUMOR VOLUME;

EID: 84890281217     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1320318110     Document Type: Article

References (26)

1. Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256):1734-1736.
2. Dong H, et al. (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 8(8):793- 800.
3. Hodi FS, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711-723.
4. Hamid O, et al. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369(2):134-144.
5. Brahmer JR, et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455-2465.
6. Wolchok JD, et al. (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2):122-133.
7. Royal RE, et al. (2010) Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 33(8):828-833.
8. Garin-Chesa P, Old LJ, Rettig WJ (1990) Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA 87(18):7235-7239.
9. Kraman M, et al. (2010) Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330(6005):827-830.
10. Hingorani SR, et al. (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7(5):469-483.
11. Erez N, Truitt M, Olson P, Arron ST, Hanahan D (2010) Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 17(2):135-147.
12. Roberts EW, et al. (2013) Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med 210(6):1137-1151.
13. Naito Y, et al. (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58(16):3491-3494.
14. Zhang L, et al. (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348(3):203-213.
15. Liang JJ, et al. (2010) High levels of expression of human stromal cell-derived factor-1 are associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 19(10):2598-2604.
16. Orimo A, et al. (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121(3):335- 348.
17. Tang D, et al. (2010) HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 29(38):5299-5310.
18. Schiraldi M, et al. (2012) HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med 209(3):551-563.
19. Schols D, Esté JA, Henson G, De Clercq E (1997) Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res 35(3):147-156.
20. Brindle K (2008) New approaches for imaging tumour responses to treatment. Nat Rev Cancer 8(2):94-107.
21. Herbein G, et al. (1998) Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 395(6698):189-194.
22. Poznansky MC, et al. (2000) Active movement of T cells away from a chemokine. Nat Med 6(5):543-548.
23. Simpson TR, et al. (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210(9):1695-1710.
24. Akishima-Fukasawa Y, et al. (2009) Prognostic significance of CXCL12 expression in patients with colorectal carcinoma. Am J Clin Pathol 132(2):202-210, quiz 307.
25. DuPage M, et al. (2011) Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 19(1):72-85.
26. Eyles J, et al. (2010) Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest 120(6):2030-2039.